DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The state-of-the-art facility is expected to be commissioned over the next three years
The company operates a chain of mid-sized multi-speciality hospitals
Clinical trial enrollment has long been a bottleneck in drug development
The inspection concluded with one minor observation in Form 483
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
The audit was completed with zero critical and zero major observations
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
Subscribe To Our Newsletter & Stay Updated
